ATE337794T1 - Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel - Google Patents

Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel

Info

Publication number
ATE337794T1
ATE337794T1 AT98909691T AT98909691T ATE337794T1 AT E337794 T1 ATE337794 T1 AT E337794T1 AT 98909691 T AT98909691 T AT 98909691T AT 98909691 T AT98909691 T AT 98909691T AT E337794 T1 ATE337794 T1 AT E337794T1
Authority
AT
Austria
Prior art keywords
muscle
nucleic acids
pharmaceutical preparations
nucleic acid
electrical current
Prior art date
Application number
AT98909691T
Other languages
English (en)
Inventor
Iacob Mathiesen
Terje Lomo
Original Assignee
Electrofect As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrofect As filed Critical Electrofect As
Application granted granted Critical
Publication of ATE337794T1 publication Critical patent/ATE337794T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/205—Applying electric currents by contact electrodes continuous direct currents for promoting a biological process
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014—External stimulators, e.g. with patch electrodes
    • A61N1/36017—External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98909691T 1997-04-03 1998-04-03 Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel ATE337794T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4259497P 1997-04-03 1997-04-03

Publications (1)

Publication Number Publication Date
ATE337794T1 true ATE337794T1 (de) 2006-09-15

Family

ID=21922760

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98909691T ATE337794T1 (de) 1997-04-03 1998-04-03 Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel

Country Status (16)

Country Link
US (1) US6110161A (de)
EP (1) EP1023107B1 (de)
JP (2) JP2001520537A (de)
KR (1) KR100427786B1 (de)
CN (1) CN1198665C (de)
AT (1) ATE337794T1 (de)
AU (1) AU733628B2 (de)
CA (1) CA2285056C (de)
DE (1) DE69835761T2 (de)
DK (1) DK1023107T3 (de)
EA (1) EA002087B1 (de)
ES (1) ES2273408T3 (de)
IL (1) IL132103A0 (de)
NO (1) NO327806B1 (de)
NZ (1) NZ337853A (de)
WO (1) WO1998043702A2 (de)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702359A (en) * 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5993434A (en) * 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
AU8444798A (en) 1997-06-30 1999-01-25 Centre National De La Recherche Scientifique Improved method for transferring nucleic acid into the striped muscle and combination therefor
IL133708A0 (en) * 1997-06-30 2001-04-30 Rhone Poulence Rorer S A Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination thereof
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US20040229363A1 (en) * 1998-06-24 2004-11-18 Ed Nolan High efficiency transfection based on low electric field strength, long pulse length
US7922709B2 (en) 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US6697669B2 (en) 1998-07-13 2004-02-24 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
AU2868200A (en) * 1999-02-08 2000-08-25 Chiron Corporation Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
US6593130B1 (en) * 1999-04-16 2003-07-15 The Regents Of The University Of California Method and apparatus for ex vivo and in vivo cellular electroporation of gene protein or drug therapy
AU2001241958A1 (en) * 2000-03-03 2001-09-17 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
AU2001264759B2 (en) 2000-05-22 2006-06-01 Merck & Co., Inc. System and method for assessing the performance of a pharmaceutical agent delivery system
US6733485B1 (en) 2001-05-25 2004-05-11 Advanced Bionics Corporation Microstimulator-based electrochemotherapy methods and systems
US20040204669A1 (en) * 2001-07-05 2004-10-14 Hofmann Gunter A. Apparatus for electroporation mediated delivery for drugs and genes
US7713740B2 (en) * 2001-08-24 2010-05-11 University Of South Florida Method of using electric fields to facilitate the entry of molecules into cells in vivo
CN1880457B (zh) 2001-10-11 2010-05-26 麦克公司 Ad6重组核酸
US7598362B2 (en) 2001-10-11 2009-10-06 Merck & Co., Inc. Hepatitis C virus vaccine
CN1612691A (zh) * 2001-11-08 2005-05-04 加利福尼亚大学董事会 纠正心脏传导障碍的方法和组合物
AU2002360648B2 (en) * 2001-12-14 2009-01-08 Genetronics, Inc. Methods for particle-assisted polynucleotide immunization using a pulsed electric field
EP1470161A1 (de) * 2002-01-18 2004-10-27 Inovio AS Bispezifische antikörper-dna-konstrukte für die intramuskuläre verabreichung
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
AU2003230601A1 (en) 2002-03-07 2003-09-22 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Clinical syringe with electrical stimulation aspects
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
CN100455328C (zh) 2002-04-16 2009-01-28 塞托·帕尔斯科技公司 借助于平移电场和电极极性反转治疗生物体部位的设备
US20040106896A1 (en) * 2002-11-29 2004-06-03 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
HUE025052T2 (en) 2004-03-08 2016-01-28 Ichor Medical Systems Inc A sharpened device for electrically mediated delivery of medical substances
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
US20080182251A1 (en) 2005-03-19 2008-07-31 Luyi Sen Ultra Low Strength Electric Field Network-Mediated Ex Vivo Gene, Protein and Drug Delivery in Cells
WO2006133911A2 (en) 2005-06-17 2006-12-21 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hepatitis c virus nucleic acid vaccine
ES2551306T3 (es) * 2006-02-13 2015-11-17 Oncolytics Biotech Inc. Uso de inmunosupresión local de baja dosis para potenciar una terapia viral oncolítica
WO2008063555A2 (en) 2006-11-17 2008-05-29 Genetronics, Inc. Methods of enhancing immune response using electroporation-assisted vaccination and boosting
EP2612867A1 (de) 2007-11-01 2013-07-10 Perseid Therapeutics LLC Immunsuppressive Polypeptide und Nucleinsäuren
CA2720166A1 (en) * 2008-04-04 2009-10-08 David B. Weiner Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
KR101652767B1 (ko) * 2008-04-04 2016-08-31 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｉｌ-28을 이용한 백신 및 면역치료제, 및 그를 사용하는 방법 및 조성물
EP2147697A1 (de) 2008-07-21 2010-01-27 Centre National De La Recherche Scientifique-CNRS Verfahren und Vorrichtung zur Anwendung elektrischer Felder in leitfähiges Material
EP2156860A1 (de) 2008-08-20 2010-02-24 Centre National De La Recherche Scientifique-CNRS Verfahren zur Herstellung isolierter Elektroden zum Einfügen elektrischer Felder in ein leitfähiges Material
US20100298697A1 (en) * 2009-05-19 2010-11-25 Medtronic, Inc. Method and devices for improved efficiency of rna delivery to cells
US8207138B2 (en) 2009-05-19 2012-06-26 Medtronic, Inc. Methods and devices for improved efficiency of RNA delivery to cells
WO2011032179A1 (en) 2009-09-14 2011-03-17 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
KR102138780B1 (ko) 2009-11-02 2020-07-29 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 구제역 바이러스(ｆｍｄｖ) 공통 단백질, 이를 위한 코딩 서열 및 이로부터 만들어진 백신
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
EP2539354B1 (de) 2010-02-08 2017-04-05 The Trustees Of The University Of Pennsylvania Für rantes kodierende nukleinsäuremoleküle sowie zusammensetzungen und verfahren damit
AU2011223753B2 (en) 2010-03-01 2014-06-26 Inovio Pharmaceuticals, Inc. A tolerable and minimally invasive skin electroporation device
MX355501B (es) 2010-09-27 2018-04-20 Inovio Pharmaceuticals Inc Star Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.
JP6077450B2 (ja) 2010-11-12 2017-02-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途
EA033467B1 (ru) 2011-01-31 2019-10-31 Univ Pennsylvania Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EA032364B1 (ru) 2011-02-11 2019-05-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
CN103717249B (zh) 2011-06-15 2017-03-22 克洛恩泰克制药股份公司 注射针和装置
KR102314421B1 (ko) 2011-07-11 2021-10-19 이노비오 파마수티컬즈, 인크. 교차-보호성 아레나바이러스 백신 및 이의 사용 방법
JP6333730B2 (ja) 2011-12-12 2018-05-30 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改善されたｉｌ−１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法
JP6407028B2 (ja) 2011-12-12 2018-10-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用
HK1210479A1 (en) 2012-04-10 2016-04-22 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
CA3194125A1 (en) 2012-04-12 2013-10-17 The Trustees Of The University Of Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
DE102012013534B3 (de) 2012-07-05 2013-09-19 Tobias Sokolowski Vorrichtung für repetitive Nervenstimulation zum Abbau von Fettgewebe mittels induktiver Magnetfelder
WO2014064534A2 (en) 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
WO2015089492A2 (en) 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
CN104812401B (zh) 2012-12-13 2017-10-13 宾夕法尼亚大学理事会 Wt1疫苗
KR20150130284A (ko) 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 백신 및 이를 이용한 치료 방법
CN105338998B (zh) 2013-03-15 2021-12-14 宾夕法尼亚大学理事会 口蹄疫病毒(fmdv)共有蛋白、其编码序列以及由其制造的疫苗
US10272144B2 (en) 2013-07-31 2019-04-30 Bioventures, Llc Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens
MX2017007187A (es) 2014-12-01 2018-01-30 Univ Pennsylvania Construcciones de anticuerpos de adn y metodo para utilizarlas.
US11491342B2 (en) 2015-07-01 2022-11-08 Btl Medical Solutions A.S. Magnetic stimulation methods and devices for therapeutic treatments
US10695575B1 (en) 2016-05-10 2020-06-30 Btl Medical Technologies S.R.O. Aesthetic method of biological structure treatment by magnetic field
US11266850B2 (en) 2015-07-01 2022-03-08 Btl Healthcare Technologies A.S. High power time varying magnetic field therapy
US20180001107A1 (en) 2016-07-01 2018-01-04 Btl Holdings Limited Aesthetic method of biological structure treatment by magnetic field
WO2017055522A1 (en) 2015-09-29 2017-04-06 Academisch Medisch Centrum Stabilized env proteins of hiv
US11253717B2 (en) 2015-10-29 2022-02-22 Btl Healthcare Technologies A.S. Aesthetic method of biological structure treatment by magnetic field
WO2017136758A1 (en) 2016-02-05 2017-08-10 Inovio Pharmaceuticals, Inc. Cancer vaccines and methods of treatment using the same
AU2017241925B2 (en) 2016-03-28 2022-01-13 Ichor Medical Systems, Inc. Method and apparatus for delivery of therapeutic agents
JP7250520B2 (ja) 2016-04-13 2023-04-03 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組換えアルテリウイルスレプリコン系およびその使用
US11464993B2 (en) 2016-05-03 2022-10-11 Btl Healthcare Technologies A.S. Device including RF source of energy and vacuum system
US11247039B2 (en) 2016-05-03 2022-02-15 Btl Healthcare Technologies A.S. Device including RF source of energy and vacuum system
US11534619B2 (en) 2016-05-10 2022-12-27 Btl Medical Solutions A.S. Aesthetic method of biological structure treatment by magnetic field
US10583287B2 (en) 2016-05-23 2020-03-10 Btl Medical Technologies S.R.O. Systems and methods for tissue treatment
US10556122B1 (en) 2016-07-01 2020-02-11 Btl Medical Technologies S.R.O. Aesthetic method of biological structure treatment by magnetic field
US11141219B1 (en) 2016-08-16 2021-10-12 BTL Healthcare Technologies, a.s. Self-operating belt
KR102718353B1 (ko) 2016-10-17 2024-10-15 얀센 파마슈티칼즈, 인코포레이티드 재조합 바이러스 레플리콘 시스템 및 그의 용도
CA3045650A1 (en) 2016-12-05 2018-06-14 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
US11344618B2 (en) 2017-08-26 2022-05-31 Academisch Medisch Centrum HIV envelope glycoprotein immunogens
CA3083532C (en) 2017-12-13 2023-09-05 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting prame and uses thereof
WO2019118764A1 (en) 2017-12-13 2019-06-20 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting muc16 and uses thereof
WO2019118760A1 (en) 2017-12-13 2019-06-20 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting mesothelin and uses thereof
KR102668476B1 (ko) 2017-12-13 2024-05-23 이노비오 파마수티컬즈, 인크. Boris를 표적으로 하는 암 백신 및 이의 용도
CN111836641A (zh) 2017-12-19 2020-10-27 杨森科学爱尔兰无限公司 乙型肝炎病毒(hbv)疫苗及其用途
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
KR20200100745A (ko) 2017-12-19 2020-08-26 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
JP7494117B2 (ja) 2018-01-19 2024-06-03 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組換えレプリコン系を使用する免疫応答の誘導および増強
WO2020076775A1 (en) 2018-10-08 2020-04-16 Janssen Pharmaceuticals, Inc. Alphavirus-based replicons for administration of biotherapeutics
US12156689B2 (en) 2019-04-11 2024-12-03 Btl Medical Solutions A.S. Methods and devices for aesthetic treatment of biological structures by radiofrequency and magnetic energy
US12558146B2 (en) 2019-04-11 2026-02-24 Btl Medical Solutions A.S. Methods and devices for aesthetic treatment of biological structures by radiofrequency and magnetic energy
EP3952984B1 (de) 2019-04-11 2024-09-04 BTL Medical Solutions a.s. Vorrichtungen zur ästhetischen behandlung biologischer strukturen durch hochfrequenz und magnetische energie
CA3140708A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
WO2020255042A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and a pyrimidine derivative
EP3986460A2 (de) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Kombination aus hepatitis-b-virus (hbv)-impfstoffen und anti-pd-1-antikörper
WO2020255010A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
CA3140588A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor
WO2020255022A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
WO2020255019A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and a quinazoline derivative
WO2020255016A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
CA3140707A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
KR20220042116A (ko) 2019-06-18 2022-04-04 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합
WO2020255013A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives
WO2020254876A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Virus-like particle delivery of hepatitis b virus (hbv) vaccines
WO2020255012A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
KR20220041080A (ko) 2019-06-18 2022-03-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합
WO2020255035A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyrimidine derivatives
CA3141003A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors
US20250041386A1 (en) 2019-06-18 2025-02-06 Janssen Sciences Ireland Unlimited Company Recombinant Interleukin 12 Construct and Uses Thereof
US20220249647A1 (en) 2019-06-18 2022-08-11 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
WO2020255018A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
CA3140702A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
CA3143679A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
WO2020255062A1 (en) 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
EP3986457A1 (de) 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Company Kohlenhydrat-nanoträger-freisetzungvon hepatitis-b-virus-(hbv)-impfstoffen
US12611545B2 (en) 2020-05-04 2026-04-28 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient
JP2023515722A (ja) 2020-05-04 2023-04-13 ビーティーエル ヘルスケア テクノロジーズ エー．エス． 患者の非アテンド式治療のためのデバイスおよび方法
US11878167B2 (en) 2020-05-04 2024-01-23 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient
CA3181680A1 (en) 2020-06-12 2021-12-16 University Of Rochester Encoding and expression of ace-trnas
IL299571A (en) 2020-07-08 2023-02-01 Janssen Sciences Ireland Unlimited Co Rna replicon vaccines against hbv
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022146654A1 (en) 2020-12-28 2022-07-07 Janssen Pharmaceuticals, Inc. Transcription activator-like effector nucleases (talens) targeting hbv
CA3260012A1 (en) 2021-10-13 2023-04-20 Btl Medical Solutions A.S. AESTHETIC TREATMENT DEVICES FOR BIOLOGICAL STRUCTURES USING RADIOFREQUENCY AND MAGNETIC ENERGY
US11896816B2 (en) 2021-11-03 2024-02-13 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient
AU2023215397A1 (en) 2022-02-07 2024-08-22 University Of Rochester Optimized sequences for enhanced trna expression or/and nonsense mutation suppression.
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1
EP4634373A1 (de) 2022-12-16 2025-10-22 University of Rochester Reparatur von dysfunktion der barriere in der speiseröhre
WO2025101685A1 (en) 2023-11-09 2025-05-15 University Of Rochester Suppression of nonsense mutations using anticodon engineered (ace)-trnas
WO2026030209A1 (en) 2024-07-29 2026-02-05 University Of Rochester Use of decoding trnas to boost protein expression or function
US20260097226A1 (en) 2024-10-08 2026-04-09 Btl Medical Solutions A.S. Devices and methods for application of a magnetic field to the nervous system

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389069A (en) * 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
US5501662A (en) * 1992-05-22 1996-03-26 Genetronics, Inc. Implantable electroporation method and apparatus for drug and gene delivery
US5304120A (en) * 1992-07-01 1994-04-19 Btx Inc. Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
US5273525A (en) * 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5318514A (en) * 1992-08-17 1994-06-07 Btx, Inc. Applicator for the electroporation of drugs and genes into surface cells
US5468223A (en) * 1992-11-30 1995-11-21 C.N.R.S. Paris Electrochemotherapy
FR2703253B1 (fr) * 1993-03-30 1995-06-23 Centre Nat Rech Scient Applicateur d'impulsions electriques pour traitement de tissus biologiques.
US5993434A (en) * 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5702359A (en) * 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
IL108775A (en) * 1994-02-25 2003-09-17 Univ Ramot Method for efficient incorporation of molecules into cells
WO1996035130A1 (en) * 1995-05-02 1996-11-07 Philips Electronics N.V. Method of and device for magnetic resonance imaging of objects
US5944710A (en) * 1996-06-24 1999-08-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
IL133708A0 (en) * 1997-06-30 2001-04-30 Rhone Poulence Rorer S A Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination thereof

Also Published As

Publication number Publication date
US6110161A (en) 2000-08-29
ES2273408T3 (es) 2007-05-01
DK1023107T3 (da) 2006-12-27
KR20010005932A (ko) 2001-01-15
JP2001520537A (ja) 2001-10-30
WO1998043702A2 (en) 1998-10-08
NZ337853A (en) 2002-03-28
NO994820D0 (no) 1999-10-04
CA2285056A1 (en) 1998-10-08
NO327806B1 (no) 2009-09-28
EP1023107A1 (de) 2000-08-02
AU6990698A (en) 1998-10-22
JP2006061701A (ja) 2006-03-09
DE69835761D1 (de) 2006-10-12
CN1198665C (zh) 2005-04-27
IL132103A0 (en) 2001-03-19
NO994820L (no) 1999-12-03
EA199900882A1 (ru) 2001-02-26
EA002087B1 (ru) 2001-12-24
KR100427786B1 (ko) 2004-04-30
AU733628B2 (en) 2001-05-17
CA2285056C (en) 2004-12-14
EP1023107B1 (de) 2006-08-30
DE69835761T2 (de) 2007-09-13
CN1276740A (zh) 2000-12-13

Similar Documents

Publication Publication Date Title
ATE337794T1 (de) Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel
Somiari et al. Theory and in vivo application of electroporative gene delivery
ATE275423T1 (de) Verabreichung der nukleinsäure in den quergestreiften muskel
DE69727958D1 (de) Zusammenstellungen und verfahren zur änderung der bioverteilung von biologischen agentien
CA2087087C (en) Molecules for iontophoretic delivery
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
DK0788392T3 (da) Elektroforetisk gen- og medicinterapi ved hjælp af inducerede elektriske felter
ATE209887T1 (de) Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel
ATE142266T1 (de) Verfahren zum transport von molekülen in eukaryotenzellen
DK592186A (da) Fremgangsmaade til udvinding af proteiner
DK0559884T3 (da) Rekombinante virusvektorer til ekspression i muskelceller
AR017866A1 (es) Metodo para incrementar las inmunorespuestas de vacunas de acidos nucleicos, composiciones farmaceuticas de aplicacion en dicho metodo, procedimientopara preparar dichas composiciones y vacunas utilizadas en dicho metodo.
ATE332725T1 (de) Verfahren zur elektropermeabilisation einzelner zellulärer und organeller strukturen
MA20411A1 (fr) Procede de preparation de polypeptides ayant l'activite du gamma-interferon humain
ATE530659T1 (de) Modulare transfektionssysteme auf der basis von nukleoproteinfilamenten
Gratieri et al. Non-invasive iontophoretic delivery of peptides and proteins across the skin
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
NO873437D0 (no) Human placenta angiogen faktor i stand til aa stimulere kapillaer endotelcelle-proteasesyntese, dna-syntese og migrasjon.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1023107

Country of ref document: EP